Grumann

Arena's Obesity Drug Not Likely to Make It

Derek, You appear to have the credentials and experience to write a more complete analysis of the prospects for Lorcaserin. This "article" is a simple opinion. You've shown your bias already, but I'd still be interested in hearing your thoughts on what might be the next steps ARNA could pursue here. With the safety issues resolved, isn't ARNA set up nicely (except for cash) to pursue more aggressive weight loss studies? And hasn't the safety issue been the primary reason they haven't yet entered into a partnership, so now that may be more likely? Isn't your declaration that Loraserin won't make it a bit premature? How about a SWOT analysis (Strengths, Weaknesses, Opportunities, Threats)?